Clinical Trials Directory

Trials / Completed

CompletedNCT04412980

Ionized Magnesium for Monitoring of Citrate-anticoagulated CVVHD

Importance of Ionized Magnesium Measurement for Monitoring of Continuous Venovenous Haemodialysis With Citrate Anticoagulation

Status
Completed
Phase
Study type
Observational
Enrollment
40 (actual)
Sponsor
University Hospital, Montpellier · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

It has been reported in several studies that ionized hypomagnesemia is associated with higher morbidity and mortality rates. During continuous renal replacement therapy with regional citrate anticoagulation (CRRT-RCA), the loss of magnesium has been reported to not be covered by magnesium concentration in ordinary dialysis fluid. This may lead to ionized hypomagnesemia. However the incidence of ionized hypomagnesemia in patients requiring CRRT-RCA remains unclear and need to be estimated to determine if ionized magnesium monitoring could be of interest. This study aim to assess the incidence of ionized hypomagnesemia induced by CRRT-RCA.

Conditions

Timeline

Start date
2020-05-01
Primary completion
2020-10-01
Completion
2020-11-23
First posted
2020-06-02
Last updated
2020-11-24

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04412980. Inclusion in this directory is not an endorsement.

Ionized Magnesium for Monitoring of Citrate-anticoagulated CVVHD (NCT04412980) · Clinical Trials Directory